Article Text

Download PDFPDF
EP1337 A primary extended cytoreductive surgery for ovarian cancer: total abdominal hysterectomy and bilateral salpingo-oophorectomy, total omentectomy, total peritonectomy, bilateral diaphragm stripping, cholecystectomy, total colectomy, splenectomy, bilateral pelvic-paraaortic lymphadenectomy, dissection of porta hepatis, liver metastasectomy, and bilateral cardiophrenic lymphadenectomy
  1. C Taskiran1,
  2. D Vatansever1,
  3. A Eraslan1,
  4. B Giray2,
  5. S Misirlioglu1,
  6. E Balik3,
  7. T Kumcular4 and
  8. M Arvas5
  1. 1Obstetrics and Gynecology, Koc University School of Medicine
  2. 2Obstetrics and Gynecology, Zeynep Kamil Training and Research Hospital
  3. 3General Surgery, Koc University School of Medicine
  4. 4Women’s Health Center, American Hospital
  5. 5Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

Abstract

Introduction/Background Ovarian cancer is the leading cause of death among gynecological malignancies. Primary cytoreduction for ovarian cancer is associated with significantly improved survival. We aimed to present a primary extended cytoreduction performed in this video.

Methodology A 37 years-old woman was admitted with abdominal swelling and pelvic pain. Pelvic examination revealed out ascites and bilateral adnexal masses. MRI showed 11-cm right adnexal mass, 7-cm left adnexal mass, omental cakes, disseminated peritoneal implants, liver metastases, and enlarged lymph nodes in the right obturator fossa. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, total peritonectomy, bilateral diaphragmatic stripping, total colectomy, splenectomy, bilateral pelvic-paraaortic lymphadenectomy, cholecystectomy, dissection of the porta hepatis, liver metastasectomy, and transabdominal cardiophrenic lymph node dissection were performed as a part of maximal primarily cytoreduction.

Results We did not encounter any grade 3 or 4 adverse event in post-operative period.

Conclusion Primary cytoreduction for ovarian cancer with no residual disease is a major impact on survival. The management of this condition should be performed with expert multidisciplinary teams in gynecological oncology.

Disclosure Nothing to disclose

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.